SynthesisDrugs in R&D2017
Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review.
Synthesis in Drugs in R&D, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.
- Clinical outcomes of intravitreal treatment for ocular toxoplasmosis: systematic review and meta-analysis.Revista da Sociedade Brasileira de Medicina Tropical · 2023Pooled it
- Anticancer proteasome inhibitors are detrimental to the growth of Toxoplasma gondii in vitro.BMC research notes · 2026Article
- Identification of UCB-9721 as a potent inhibitor of MyoA, the essential class XIV myosin motor of apicomplexan parasites.bioRxiv : the preprint server for biology · 2026Article
- Prophylactic Administration of Gypsophila oldhamiana Extract Restricts Acute Toxoplasma gondii Infection via the DC-IL-12-CD8⁺ T Cell Axis in a Murine Model.Acta parasitologica · 2026Article
- Is heme metabolism a promising drug target in Toxoplasma gondii?PLoS pathogens · 2026Article
- Myricetin InhibitsCells · 2026Article
- Next-Generation Vaccines Against Neglected Diseases: New Promises from Genetically Modified Live-Attenuated Parasites and RNA Vaccines.Microorganisms · 2026Review
- Inhibitors of the FASII Metabolic Pathway inMicroorganisms · 2026Review
- Pyrimethamine Restores KEAP1-Mediated Degradation of Select NRF2 Mutants in Esophageal Squamous Cell Carcinoma.Cancers · 2026Article
- Intravitreal cotrimoxazole as adjuvant therapy for active ocular toxoplasmosis: a case series and literature review.Journal of ophthalmic inflammation and infection · 2026Article
- Evaluation of the potential therapeutic efficacy of Cerastes cerastes venom in acute experimental toxoplasmosis.Parasites & vectors · 2026Article
- GSK3β/HIF-1α signaling-dependent anti-parasite effect ofiScience · 2026Article
- Case Report: Unusual inferonasal peripheral retinal involvement in ocular toxoplasmosis: a case report with diagnostic and therapeutic implications.Frontiers in immunology · 2026Article
- BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion.Frontiers in cellular and infection microbiology · 2026Article
- Therapeutic effect of baicalein as an antiparasitic agent againstJournal of Zhejiang University. Science. B · 2025Article
- Structure-Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors.ChemMedChem · 2025Article
- New derivatives of 6-nitrocoumarin-3-thiosemicarbazone exhibit improved antiparasitic activity in the placenta againstAntimicrobial agents and chemotherapy · 2025Article
- Evaluation of anti-Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Article
- NRF2 activation in cancer and overview of NRF2 small molecule inhibitors.Archives of pharmacal research · 2025Review
- Protective Efficacy Induced by Virus-like Particles Expressing Dense Granule Protein 5 ofVaccines · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionApproximately a third of the population worldwide is chronically infected with Toxoplasma gondii. Pyrimethamine-based regimens are recommended for the treatment of toxoplasmosis.
objectiveThe aim was to evaluate the safety profile of pyrimethamine-based treatment for the three main Toxoplasma manifestations: toxoplasmic encephalitis (TE), ocular toxoplasmosis, and congenital toxoplasmosis.
methodsPubMed, Cochrane Library, and Google Scholar databases were searched through August 1, 2016. Randomized, observational, prospective/retrospective, and cohort studies were eligible. Thirty-one studies were included with a total of 2975 patients. Of these, 13 were in congenital toxoplasmosis (n = 929), 11 in ocular toxoplasmosis (n = 1284), and seven in TE (n = 687). Across manifestations, adverse event (AE)-related treatment discontinuation and/or change in therapy involved ≤37% of patients and occurred in >55% of studies: 100% for ocular toxoplasmosis, 57.1% for TE, and 61.5% for congenital toxoplasmosis. The most commonly observed AEs were bone marrow suppression, dermatologic, and gastrointestinal (GI). The prevalence of bone marrow suppression-related AEs was ≤50% in congenital toxoplasmosis, ≤42.7% in TE, and ≤9.0% in ocular toxoplasmosis. The frequency of GI and dermatologic AEs were ≤100 and ≤11.1%, respectively, for ocular toxoplasmosis, ≤10.7 and ≤17.9% for TE, and ≤10.8 and ≤2.1% for congenital toxoplasmosis. Steven-Johnson syndrome was reported in two patients with ocular toxoplasmosis and one with TE.
conclusionThe AE profile associated with pyrimethamine-based treatments differed by each manifestation of toxoplasmosis and within a given manifestation. Hematologic AEs occurred across all manifestations indicating the importance of monitoring the blood of patients administered pyrimethamine-based regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.